Advertisement

COVID-19 vaccination during pregnancy: coverage and safety

Published:August 09, 2021DOI:https://doi.org/10.1016/j.ajog.2021.08.007

      Background

      Concerns have been raised regarding a potential surge of COVID-19 in pregnancy, secondary to the rising numbers of COVID-19 in the community, easing of societal restrictions, and vaccine hesitancy. Although COVID-19 vaccination is now offered to all pregnant women in the United Kingdom; limited data exist on its uptake and safety.

      Objective

      This study aimed to investigate the uptake and safety of COVID-19 vaccination among pregnant women.

      Study Design

      This was a cohort study of pregnant women who gave birth at St George’s University Hospitals National Health Service Foundation Trust, London, United Kingdom, between March 1, 2020, and July 4, 2021. The primary outcome was uptake of COVID-19 vaccination and its determinants. The secondary outcomes were perinatal safety outcomes. Data were collected on COVID-19 vaccination uptake, vaccination type, gestational age at vaccination, and maternal characteristics, including age, parity, ethnicity, index of multiple deprivation score, and comorbidities. Further data were collected on perinatal outcomes, including stillbirth (fetal death at ≥24 weeks’ gestation), preterm birth, fetal and congenital abnormalities, and intrapartum complications. Pregnancy and neonatal outcomes of women who received the vaccine were compared with that of a matched cohort of women with balanced propensity scores. Effect magnitudes of vaccination on perinatal outcomes were reported as mean differences or odds ratios with 95% confidence intervals. Factors associated with antenatal vaccination were assessed with logistic regression analysis.

      Results

      Data were available for 1328 pregnant women of whom 140 received at least 1 dose of the COVID-19 vaccine before giving birth and 1188 women who did not; 85.7% of those vaccinated received their vaccine in the third trimester of pregnancy and 14.3% in the second trimester of pregnancy. Of those vaccinated, 127 (90.7%) received a messenger RNA vaccine and 13 (9.3%) a viral vector vaccine. There was evidence of reduced vaccine uptake in younger women (P=.001), women with high levels of deprivation (ie, fifth quintile of the index of multiple deprivation; P=.008), and women of Afro-Caribbean or Asian ethnicity compared with women of White ethnicity (P<.001). Women with prepregnancy diabetes mellitus had increased vaccine uptake (P=.008). In the multivariable model the fifth deprivation quintile (most deprived) (adjusted odds ratio, 0.10; 95% confidence interval, 0.02–0.10; P=.003) and Afro-Caribbean ethnicity (adjusted odds ratio, 0.27; 95% confidence interval, 0.06–0.85; P=.044) were significantly associated with lower antenatal vaccine uptake, whereas prepregnancy diabetes mellitus was significantly associated with higher antenatal vaccine uptake (adjusted odds ratio, 10.5; 95% confidence interval, 1.74–83.2; P=.014). In a propensity score–matched cohort, the rates of adverse pregnancy outcomes of 133 women who received at least 1 dose of the COVID-19 vaccine in pregnancy were similar to that of unvaccinated pregnant women (P>.05 for all): stillbirth (0.0% vs 0.2%), fetal abnormalities (2.2% vs 2.5%), postpartum hemorrhage (9.8% vs 9.0%), cesarean delivery (30.8% vs 34.1%), small for gestational age (12.0% vs 12.8%), maternal high-dependency unit or intensive care admission (6.0% vs 4.0%), or neonatal intensive care unit admission (5.3% vs 5.0%). Intrapartum pyrexia (3.7% vs 1.0%; P=.046) was significantly increased but the borderline statistical significance was lost after excluding women with antenatal COVID-19 infection (P=.079). Mixed-effects Cox regression showed that vaccination was not significantly associated with birth at <40 weeks’ gestation (hazard ratio, 0.93; 95% confidence interval, 0.71–1.23; P=.624).

      Conclusion

      Of pregnant women eligible for COVID-19 vaccination, less than one-third accepted COVID-19 vaccination during pregnancy, and they experienced similar pregnancy outcomes with unvaccinated pregnant women. There was lower uptake among younger women, non-White ethnicity, and lower socioeconomic background. This study has contributed to the body of evidence that having COVID-19 vaccination in pregnancy does not alter perinatal outcomes. Clear communication to improve awareness among pregnant women and healthcare professionals on vaccine safety is needed, alongside strategies to address vaccine hesitancy. These strategies include postvaccination surveillance to gather further data on pregnancy outcomes, particularly after first-trimester vaccination, and long-term infant follow-up.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Roberton T.
        • Carter E.D.
        • Chou V.B.
        • et al.
        Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study.
        Lancet Glob Health. 2020; 8: e901-e908
        • Viana J.
        • van Dorp C.H.
        • Nunes A.
        • et al.
        Controlling the pandemic during the SARS-CoV-2 vaccination rollout.
        Nat Commun. 2021; 12: 3674
        • Kalafat E.
        • O’Brien P.
        • Heath P.T.
        • et al.
        Benefits and potential harms of COVID-19 vaccination during pregnancy: evidence summary for patient counseling.
        Ultrasound Obstet Gynecol. 2021; 57: 681-686
        • American College of Obstetricians and Gynaecologists
        Vaccinating pregnant and lactating patients against COVID-19 practice advisory. 2021.
        (Available at:)
        • Gray K.J.
        • Bordt E.A.
        • Atyeo C.
        • et al.
        COVID-19 vaccine response in pregnant and lactating women: a cohort study. medRxiv.
        (Preprint posted online March 8, 2021)
        • Pfizer
        Pfizer and BioNTech commence global clinical trial to evaluate COVID-19 vaccine in pregnant women. 2021.
        (Available at:)
        • US National Library of Medicine
        ClinicalTrials.gov. A study of Ad26.COV2.S in healthy pregnant participants (COVID-19) (HORIZON 1). 2021.
        (Available at:)
        • Skirrow H.
        • Barnett S.
        • Bell S.
        • et al.
        Women’s views on accepting COVID-19 vaccination during and after pregnancy, and for their babies: a multi-methods study in the UK. medRxiv.
        (Preprint posted online May 3, 2021)
        • Public Health England
        JCVI issues new advice on COVID-19 vaccination for pregnant women. 2021.
        (Available at:)
        • International Federation of Gynecology and Obstetrics
        COVID-19 vaccination for pregnant and breastfeeding women. 2021.
        (Available at:)
        • Joint Committee on Vaccination and Immunisation
        Advice on priority groups for COVID-19 vaccination. 2021.
        (Available at:)
        • Royal College of Obstetricians and Gynaecologists
        Coronavirus (COVID-19) vaccination in pregnancy, information for healthcare professionals. 2021.
        (Available at:)
        https://www.rcog.org.uk/covid-vaccine
        Date accessed: July 7, 2021
        • Public Health England
        COVID-19 vaccination: a guide to phase 2 of the programme. 2020.
        (Available at:)
        • National Health Service
        Coronavirus (COVID-19) vaccines. 2021.
        (Available at:)
        • Poon L.C.
        • Tan M.Y.
        • Yerlikaya G.
        • Syngelaki A.
        • Nicolaides K.H.
        Birth weight in live births and stillbirths.
        Ultrasound Obstet Gynecol. 2016; 48: 602-606
        • Centers for Disease Control and Prevention
        Pfizer-BioNTech COVID-19 vaccine overview and safety. 2021.
        (Available at:)
        • Wang E.W.
        • Parchem J.G.
        • Atmar R.L.
        • Clark E.H.
        SARS-CoV-2 vaccination during pregnancy: a complex decision.
        Open Forum Infect Dis. 2021; 8: ofab180
        • Skjefte M.
        • Ngirbabul M.
        • Akeju O.
        • et al.
        COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries.
        Eur J Epidemiol. 2021; 36: 197-211
        • Mathur R.
        • Rentsch C.T.
        • Morton C.E.
        • et al.
        Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform.
        Lancet. 2021; 397: 1711-1724
        • Donaldson B.
        • Jain P.
        • Holder B.S.
        • Lindsey B.
        • Regan L.
        • Kampmann B.
        What determines uptake of pertussis vaccine in pregnancy? A cross sectional survey in an ethnically diverse population of pregnant women in London.
        Vaccine. 2015; 33: 5822-5828
        • Anderson E.
        • Brigden A.
        • Davies A.
        • Shepherd E.
        • Ingram J.
        Maternal vaccines during the COVID-19 pandemic: a qualitative interview study with UK pregnant women.
        Midwifery. 2021; 100: 103062
        • Chmielewska B.
        • Barratt I.
        • Townsend R.
        • et al.
        Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis.
        Lancet Glob Health. 2021; 9: e759-e772
        • Wilcox C.R.
        • Calvert A.
        • Metz J.
        • et al.
        Determinants of influenza and pertussis vaccination uptake in pregnancy: a multicenter questionnaire study of pregnant women and healthcare professionals.
        Pediatr Infect Dis J. 2019; 38: 625-630
        • Gall S.A.
        • Myers J.
        • Pichichero M.
        Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels.
        Am J Obstet Gynecol. 2011; 204: 334.e1-334.e5
        • Shimabukuro T.T.
        • Kim S.Y.
        • Myers T.R.
        • et al.
        Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons.
        N Engl J Med. 2021; 384: 2273-2282
        • Bookstein Peretz S.
        • Regev N.
        • Novick L.
        • et al.
        Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
        Ultrasound Obstet Gynecol. 2021; ([Epub ahead of print])
        • Townsend R.
        • Chmielewska B.
        • Barratt I.
        • et al.
        Global changes in maternity care provision during the COVID-19 pandemic: a systematic review and meta-analysis.
        EClinicalMedicine. 2021; 37: 100947
        • Sacinti K.G.
        • Kalafat E.
        • Sukur Y.E.
        • Koc A.
        Increased incidence of first-trimester miscarriage during the COVID-19 pandemic.
        Ultrasound Obstet Gynecol. 2021; 57: 1013-1014
        • la Cour Freiesleben N.
        • Egerup P.
        • Hviid K.V.R.
        • et al.
        SARS-CoV-2 in first trimester pregnancy: a cohort study.
        Hum Reprod. 2021; 36: 40-47
        • National Institutes of Health
        NIH begins study of COVID-19 vaccination during pregnancy and postpartum.
        US Department of Health and Human Services, 2021 (Available at:)
        • Royal College of Obstetricians and Gynaecologists
        Maternity colleges express concern over vaccine hesitancy in pregnant women. 2021.
        (Available at:)